Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Vanda Pharmaceuticals
VNDA
Vanda Pharmaceuticals
Rising Costs And Concentration Will Thwart Stability Yet Spark Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
23 Aug 25
Updated
23 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$5.00
5.0% undervalued
intrinsic discount
23 Aug
US$4.75
Loading
1Y
-13.5%
7D
4.2%
Author's Valuation
US$5.0
5.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$5.0
5.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-67m
422m
2014
2017
2020
2023
2025
2026
2028
Revenue US$422.2m
Earnings US$68.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
22.66%
Biotech revenue growth rate
11.95%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$68.62m
Earnings '28
x
5.41x
PE Ratio '28
=
US$371.30m
Market Cap '28
US$371.30m
Market Cap '28
/
61.50m
No. shares '28
=
US$6.04
Share Price '28
US$6.04
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$4.96
Fair Value '25
